Pretomanid + Moxifloxacin + Pyrazinamide
“PaMZ” was the first novel multi-drug TB treatment to undergo clinical testing in the new regimen development paradigm. It consisted of pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). PaMZ was tested in the Phase 2a NC-001 trial, in which it killed TB bacteria faster when compared with the current TB regimen (HRZE), as well as other experimental regimens over the first two weeks of treatment. It was subsequently tested in NC-002, in which it met its primary endpoint after eight weeks treatment. In 2015, PaMZ progressed to a Phase 3 trial, known as STAND.
The STAND trial was placed on partial clinical hold, during which time more promising trial results on the BPaMZ regimen became available. The delay in enrollment caused by the hold resulted in the convergence of estimated timelines for the advancement of PaMZ and BPaMZ. Given the superior results of BPaMZ and the similar development timelines, TB Alliance has taken the decision to advance the BPaMZ regimen instead of reopening STAND to enrollment. All patients enrolled in the STAND trial have been followed and monitored as per protocol, completing their treatment course and two years of follow-up monitoring.
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial